Of note, a previous study (85) showed that a 7-day regimen of daily injections of 25 mg/kg Memantine, an NMDA receptor antagonist that is a commonly prescribed to patients with AD, reduced cortical and hippocampal KCC2 expression while simultaneously, attenuated the behavioral response to GABAAR activation with diazepam. Here, SLC12A5 is linked to Alzheimer disease.